Novo Nordisk's crazy growth impresses analyst: "My estimates have been exceeded"
Growth is not guaranteed for a company the size of the Danish giant, says Sydbank analyst Søren Løntoft Hansen on a recent guidance upgrade.
by marketwire, translated by daniel pedersen
A guidance upgrade from Novo Nordisk had been in the cards, as demand for obesity drug Wegovy had already proved massive.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
